Last reviewed · How we verify
ATV/r + TDF/FTC or DRV/r + TDF/FTC
ATV/r + TDF/FTC or DRV/r + TDF/FTC is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Juan A. Arnaiz. It is currently in Phase 3 development for HIV-1 infection (treatment-naïve or treatment-experienced patients). Also known as: PI-Based Regimens.
This is a combination antiretroviral regimen that uses protease inhibitors (boosted with ritonavir) plus nucleoside reverse transcriptase inhibitors to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes.
This is a combination antiretroviral regimen that uses protease inhibitors (boosted with ritonavir) plus nucleoside reverse transcriptase inhibitors to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes. Used for HIV-1 infection (treatment-naïve or treatment-experienced patients).
At a glance
| Generic name | ATV/r + TDF/FTC or DRV/r + TDF/FTC |
|---|---|
| Also known as | PI-Based Regimens |
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
ATV/r (atazanavir/ritonavir) or DRV/r (darunavir/ritonavir) are protease inhibitors that prevent HIV protease from cleaving viral polyproteins, while TDF/FTC (tenofovir/emtricitabine) are nucleoside reverse transcriptase inhibitors that block reverse transcriptase activity. Ritonavir acts as a pharmacokinetic booster, increasing protease inhibitor levels. Together, these agents target two critical steps in the HIV replication cycle.
Approved indications
- HIV-1 infection (treatment-naïve or treatment-experienced patients)
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Elevated bilirubin (atazanavir)
- Renal impairment (tenofovir-related)
- Bone density loss
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (PHASE3)
- Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (PHASE3)
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years (PHASE3)
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
- A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATV/r + TDF/FTC or DRV/r + TDF/FTC CI brief — competitive landscape report
- ATV/r + TDF/FTC or DRV/r + TDF/FTC updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI
Frequently asked questions about ATV/r + TDF/FTC or DRV/r + TDF/FTC
What is ATV/r + TDF/FTC or DRV/r + TDF/FTC?
How does ATV/r + TDF/FTC or DRV/r + TDF/FTC work?
What is ATV/r + TDF/FTC or DRV/r + TDF/FTC used for?
Who makes ATV/r + TDF/FTC or DRV/r + TDF/FTC?
Is ATV/r + TDF/FTC or DRV/r + TDF/FTC also known as anything else?
What drug class is ATV/r + TDF/FTC or DRV/r + TDF/FTC in?
What development phase is ATV/r + TDF/FTC or DRV/r + TDF/FTC in?
What are the side effects of ATV/r + TDF/FTC or DRV/r + TDF/FTC?
What does ATV/r + TDF/FTC or DRV/r + TDF/FTC target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease; HIV reverse transcriptase
- Manufacturer: Juan A. Arnaiz — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (treatment-naïve or treatment-experienced patients)
- Also known as: PI-Based Regimens
- Compare: ATV/r + TDF/FTC or DRV/r + TDF/FTC vs similar drugs
- Pricing: ATV/r + TDF/FTC or DRV/r + TDF/FTC cost, discount & access